BioSig Technologies Inc has announced that Kansas City Heart Institute at Overland Park Regional Medical Center in Kansas City, USA, has signed a purchase agreement to acquire its PURE EP System.
Following its evaluation of BioSig's PURE EP System, Overland Park Regional Medical Center (OPRMC) has signed an agreement to purchase the technology under the terms of the company's new program.
The agreement represents BioSig's first commercial adoption since it announced the national launch of its PURE EP System, supported by The company's new commercial structure and clinical support teams. The agreement also represents BioSig's first national purchasing agreement.
"Establishing a contract with a leading national hospital network is a milestone achievement for BioSig Technologies," commented Gray Fleming, chief commercialization officer of BioSig Technologies in a statement.
READ: BioSig Technologies gets repeat 'Outperform' tag, $4 price target from Noble Capital
"A leasing option provides a cost-effective and efficient pathway for hospitals to acquire our technology. As a Company that prioritizes physician experience and throughput, we believe a leasing program supports the clinical evolution of PURE EP as we continue upgrading and enhancing our technology based on physician feedback," he added.
Kenneth L. Londoner, chairman and CEO of BioSig Technologies said: "We are pleased to announce our first purchase agreement since we transformed the commercial capabilities under new management. The company is excited about our clinical collaboration with Dr Lakkireddy and the physician faculty at Overland Park. As physician advocates, we are proud of our commitment to and alignment with the world-class arrhythmia program at Kansas City Heart Rhythm Institute and thank them for their continued support of our technology."
The Kansas City Heart Rhythm Institute at the HCA Midwest Health Heart and Vascular Institute brings the highest quality clinical care, research and arrhythmia education to Kansas City. There are eight practicing Electrophysiologist. Locations include three Electrophysiology Practice sites in the Greater Kansas City Area as well as one outreach site location and Electrophysiology services in four hospitals.
Overland Park Regional Medical Center is a licensed 343-bed facility offering acute medical care services to our patients. The hospital campus features four medical office buildings, two pharmacies, and the offices of more than 100 physicians.
Dr Lakkireddy, executive medical director for the Kansas City Heart Rhythm Institute and Professor of Medicine at the University of Missouri Columbia and University of Nevada Las Vegas and Chief of Electrophysiology at Overland Park Medical Center commented: "This technology will be an instrumental part of Kansas City Heart Rhythm Institute's continued quest to provide superior world class care for patients. This technology could potentially enhance our ability to improve efficacy and safety of heart rhythm procedures and thereby positively impact workflow and subsequently, patient outcomes."
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.
The company's first product, PURE EP System, is a novel signal processing and acquisition platform designed to extract advanced diagnostic and therapeutic data that enhances physician workflow and increases throughput. PURE EP(T.M.) was engineered to address the limitations of existing E.P. technologies by empowering physicians with superior signals and actionable insights.
To date, over 75 physicians have completed over 2,500 patient cases with the PURE EP System. The company is in a national commercial launch of the PURE EP System. The technology is in regular use in some of the country's leading centers of excellence, including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at St. David's Medical Center.
Contact the author at jon.hopkins@proactiveinvestors.com